Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

120.64USD
18 Jun 2019
Change (% chg)

$4.91 (+4.24%)
Prev Close
$115.73
Open
$115.37
Day's High
$121.00
Day's Low
$115.10
Volume
1,066,686
Avg. Vol
567,400
52-wk High
$197.00
52-wk Low
$114.27

Select another date:

Wed, May 29 2019

Photo

Allergan to recall textured breast implants in Canada

Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

UPDATE 1-Allergan to recall textured breast implants in Canada

May 28 Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

Allergan to recall textured breast implants in Canada

May 28 Allergan Plc said on Tuesday it will voluntarily recall its textured breast implants from the Canadian market, after the country's health regulator suspended the company's licenses for its Biocell implants, citing increased risk of cancer.

Allergan's Vraylar wins FDA approval for bipolar depression

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

REFILE-UPDATE 1-Allergan's Vraylar wins U.S. FDA approval for bipolar depression

May 28 Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

Allergan's Vraylar wins FDA approval for bipolar depression

May 28 Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, making it a treatment option for a full spectrum of the condition's cyclical symptoms, the company said on Monday.

UPDATE 3-Allergan CEO says company is urgently looking at all options to boost share price

May 7 Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

Allergan reports bigger first-quarter loss on $2.5 bln charge

May 7 Allergan Plc posted a bigger first-quarter loss on Tuesday as it recorded a charge of about $2.5 billion related to the clinical failure of its depression treatment candidate rapastinel.

UPDATE 3-Allergan CEO Saunders wins vote to keep chairman role

NEW YORK, May 1 Allergan Plc shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

CORRECTED-UPDATE 1-Allergan CEO Saunders wins vote to keep chairman role

NEW YORK, May 1 Allergan Plc shareholders have voted down a non-binding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

Select another date: